Editorial Standards · Updated September 2026

Corrections

ClearMetabolic publishes a public corrections log for substantive edits to provider data, pricing claims, or clinical statements. Minor edits (typos, formatting) are not logged. Material changes are.

How to Report a Correction

If you find a factual error on any page, email hello@clearmetabolic.com with:

• The page URL
• The specific claim you believe is incorrect
• The source supporting the correct version (link or document)

We respond to factual-error reports within 7 days. Confirmed errors are corrected promptly and added to the log below. We do not adjust opinion-based content (review tone, ClearScore weighting, ranking position) in response to provider requests.

What Triggers a Logged Correction

• Pricing data that turns out to be incorrect or outdated by more than one billing cycle
• Provider attributes (states served, medications offered, insurance acceptance) that are misstated
• Clinical claims (dosing, side effect rates, contraindications) that contradict the FDA label or current peer-reviewed source
• ClearScore calculations that contained a data input error
• Misattribution of statements, citations, or quotes

Corrections Log

September 1, 2026: Stale Lilly Direct vial pricing and Wegovy self-pay figures

A scheduled pricing audit found three pages still carrying Lilly Direct self-pay vial prices from before Lilly's February 2026 price cut. Zepbound Cost in 2026 and Cheapest Tirzepatide Online listed Zepbound vials at $349-$699/mo (with 12.5mg and 15mg described as unavailable via vial), and the current price is $299/mo for 2.5mg, $399/mo for 5mg, and $449/mo for 7.5mg through 15mg, subject to a 45-day refill window on the higher doses. Mounjaro Cost in 2026 described a Mounjaro-branded Lilly Direct vial program at the same stale $349/$499 prices. Lilly's self-pay tirzepatide vials are dispensed only under the Zepbound label (its FDA-approved weight-management indication), so the page now makes clear that cash-pay Mounjaro pens transact near list price and the discounted vial route requires a Zepbound prescription. Wegovy Insurance Coverage in 2026 still quoted NovoCare Pharmacy's old flat $499/mo self-pay price and the retired "$0/mo for 13 fills" savings-card headline. NovoCare's current tiered pricing runs $149-$399/mo by formulation and dose, and the savings card is $25/mo with a $100/month cap. That page was also missing the Medicare GLP-1 Bridge, which now covers Wegovy for eligible beneficiaries at $50/mo through 12/31/2027. All four pages have been corrected and their verification stamps refreshed. Found during a scheduled monthly pricing audit.

August 26, 2026: STEP 8 trial misattribution on the Ozempic page

Our Ozempic medication profile described the STEP 8 trial as a comparison of semaglutide 2.4 mg against semaglutide 1 mg, and attributed a 12.2% weight loss figure at 68 weeks to the 1 mg dose. STEP 8 actually compared weekly semaglutide 2.4 mg against daily liraglutide 3 mg (15.8% vs 6.4% body weight loss at 68 weeks, JAMA 2022). The page has been corrected to cite STEP 8 accurately and now uses SUSTAIN trial data for 1 mg dose expectations. Found during a scheduled content review.

August 21, 2026: GLP-1 copay card savings caps

Our copay cards and patient assistance guide listed the 2025 manufacturer savings caps (up to $563 per fill for Zepbound, $573 for Mounjaro, and $500 for Wegovy) after both manufacturers reduced them for 2026. For commercially insured patients whose plan covers the medication, the current caps are $100 per 1-month fill for Zepbound ($1,300 annual cap), $150 for Mounjaro ($1,950 annual cap), $225 per 28-day fill for Wegovy (roughly $4,600 annual cap), and $100 per fill for Ozempic ($1,001 annual cap). The guide has been corrected and now carries an in-page correction notice. Reported by a reader. Thank you.

For our full editorial standards, see the editorial policy. For data and pricing methodology, see the methodology page.